Morooka et al. demonstrated that tolvaptan can ameliorate glomerulosclerosis and tubulointerstitial fibrosis and improve renal dysfunction concomitantly by suppressing activated V2R, V1aR, renin, endothelin-1, aquaporin-2 in rats with hypertensive heart failure [32]. Here, EDN1 is linked to glomerulosclerosis.